Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
Rapid Micro Biosystems (NASDAQ:RPID) reported Q2 2025 financial results, with total revenue reaching $7.3 million, up 10% year-over-year. The company demonstrated strong performance with recurring revenue growing 15% to $4.4 million and service revenue increasing 18% to $2.5 million.
The company secured a significant $45 million term loan facility with Trinity Capital, with $20 million funded at closing. Despite a net loss of $11.9 million, RPID showed improvement in gross margin, reaching positive 4% compared to negative 3% in Q2 2024. The company placed four new Growth Direct systems and completed two system validations during the quarter.
RPID reaffirmed its full-year 2025 revenue guidance of at least $32.0 million. The company ended Q2 with approximately $32 million in cash, cash equivalents, short-term investments, and restricted cash.
Rapid Micro Biosystems (NASDAQ:RPID) ha comunicato i risultati finanziari del secondo trimestre 2025, con ricavi totali pari a $7,3 milioni, in crescita del 10% su base annua. L'azienda ha mostrato una solida performance con ricavi ricorrenti in aumento del 15% a $4,4 milioni e ricavi da servizi saliti del 18% a $2,5 milioni.
L'azienda ha ottenuto un importante fido a termine da $45 milioni con Trinity Capital, di cui $20 milioni erogati alla chiusura. Nonostante una perdita netta di $11,9 milioni, RPID ha migliorato il margine lordo, arrivando a un +4% rispetto al -3% del Q2 2024. Nel trimestre sono stati installati quattro nuovi sistemi Growth Direct e completate due convalide di sistema.
RPID ha riaffermato la sua previsione di ricavi per l'intero 2025 di almeno $32,0 milioni. Al termine del Q2 la società disponeva di circa $32 milioni in liquidità, equivalenti, investimenti a breve termine e contanti vincolati.
Rapid Micro Biosystems (NASDAQ:RPID) presentó los resultados financieros del 2T 2025, con ingresos totales de $7,3 millones, un aumento del 10% interanual. La compañía mostró buen desempeño con ingresos recurrentes creciendo un 15% hasta $4,4 millones y los ingresos por servicios subiendo un 18% hasta $2,5 millones.
La empresa aseguró una línea de préstamo a plazo de $45 millones con Trinity Capital, de la cual $20 millones se desembolsaron al cierre. A pesar de una pérdida neta de $11,9 millones, RPID mejoró su margen bruto, alcanzando un 4% positivo frente al -3% del 2T 2024. Durante el trimestre se instalaron cuatro nuevos sistemas Growth Direct y se completaron dos validaciones de sistema.
RPID reafirmó su guía de ingresos para todo 2025 de al menos $32,0 millones. La compañía cerró el 2T con aproximadamente $32 millones en efectivo, equivalentes de efectivo, inversiones a corto plazo y efectivo restringido.
Rapid Micro Biosystems (NASDAQ:RPID)는 2025년 2분기 실적을 발표했다. 총매출은 730만 달러로 전년 동기 대비 10% 증가했다. 회사는 반복 매출이 15% 증가해 440만 달러를 기록했고, 서비스 매출은 18% 늘어 250만 달러가 됐다.
회사는 Trinity Capital과 함께 4,500만 달러 규모의 만기 대출 시설을 확보했으며, 그중 2,000만 달러가 종결 시점에 지급됐다. 순손실 1,190만 달러에도 불구하고 RPID는 매출총이익이 개선되어 전년 동기 -3%에서 이번 분기에는 +4%로 전환했다. 분기 중 4대의 신규 Growth Direct 시스템을 설치하고 2건의 시스템 검증을 완료했다.
RPID는 2025년 전체 매출 가이던스를 최소 3,200만 달러로 재확인했다. 회사는 2분기 말 현금 및 현금성자산, 단기투자 및 제한 현금으로 약 3,200만 달러를 보유하고 있었다.
Rapid Micro Biosystems (NASDAQ:RPID) a publié ses résultats du T2 2025, avec un chiffre d'affaires total de 7,3 M$, en hausse de 10% sur un an. La société a affiché de bonnes performances avec des revenus récurrents en hausse de 15% à 4,4 M$ et des revenus de services en hausse de 18% à 2,5 M$.
L'entreprise a obtenu une importante facilité de prêt à terme de 45 M$ auprès de Trinity Capital, dont 20 M$ ont été débloqués à la clôture. Malgré une perte nette de 11,9 M$, RPID a amélioré sa marge brute, atteignant +4% contre -3% au T2 2024. Au cours du trimestre, la société a installé quatre nouveaux systèmes Growth Direct et finalisé deux validations de système.
RPID a réaffirmé sa prévision de chiffre d'affaires pour 2025 d'au moins 32,0 M$. La société a terminé le T2 avec environ 32 M$ en liquidités, équivalents de trésorerie, placements à court terme et trésorerie restreinte.
Rapid Micro Biosystems (NASDAQ:RPID) meldete die Finanzergebnisse für Q2 2025, wobei die Gesamtumsätze 7,3 Mio. USD erreichten, ein Anstieg von 10 % gegenüber dem Vorjahr. Das Unternehmen zeigte eine starke Entwicklung mit wiederkehrenden Umsätzen, die um 15 % auf 4,4 Mio. USD wuchsen, und Serviceumsätzen, die um 18 % auf 2,5 Mio. USD zunahmen.
Das Unternehmen sicherte sich eine bedeutende Fremdfinanzierungszusage (Term Loan) über 45 Mio. USD mit Trinity Capital, davon wurden bei Closing 20 Mio. USD ausgezahlt. Trotz eines Nettoverlusts von 11,9 Mio. USD verbesserte RPID die Bruttomarge und erzielte +4 % gegenüber -3 % im Q2 2024. Im Quartal wurden vier neue Growth Direct Systeme installiert und zwei Systemvalidierungen abgeschlossen.
RPID bestätigte erneut seine Umsatzprognose für das Gesamtjahr 2025 von mindestens 32,0 Mio. USD. Zum Ende des Q2 verfügte das Unternehmen über rund 32 Mio. USD an Zahlungsmitteln, Zahlungsmitteläquivalenten, kurzfristigen Anlagen und gebundenen Geldern.
- Revenue growth of 10% year-over-year to $7.3 million
- Recurring revenue increased 15% to $4.4 million
- Service revenue grew 18% to $2.5 million
- Secured $45 million term loan facility with favorable terms
- Gross margin improved to positive 4% from negative 3% year-over-year
- Operating expenses decreased by 6% to $12.4 million
- Net loss per share improved to $0.27 from $0.29 year-over-year
- Net loss of $11.9 million despite revenue growth
- Fewer system validations (2) compared to Q2 2024 (5)
- Fewer Growth Direct system placements (4) compared to Q2 2024 (5)
- Cash position of $32 million may require additional financing despite new loan facility
Insights
Rapid Micro shows modest 10% revenue growth with improving margins, but still operates at significant losses despite securing new financing.
Rapid Micro Biosystems' Q2 results paint a mixed picture with modest improvements alongside persistent challenges. The company achieved $7.3 million in quarterly revenue, reflecting 10% year-over-year growth, with recurring revenue increasing at a healthier 15% rate to reach $4.4 million. This recurring revenue component, now representing approximately 60% of total revenue, provides some stability to their business model.
The most encouraging sign is the gross margin improvement, which turned positive at 4% compared to negative 3% in Q2 2024 - a 7 percentage point improvement. This suggests their efficiency initiatives are beginning to yield results, though margins remain dangerously thin for a technology company.
However, significant concerns persist. Despite reducing operating expenses by 6% to $12.4 million, the company still posted a substantial net loss of $11.9 million for the quarter. While this represents a slight improvement from the $12.6 million loss in Q2 2024, the company continues to burn cash at an alarming rate relative to its revenue base.
The newly secured $45 million term loan facility (with $20 million funded upfront) provides critical runway, considering their $32 million cash position as of June 30. However, this additional debt adds financial burden and underscores their continued reliance on external financing rather than operational self-sufficiency.
With management reaffirming full-year revenue guidance of at least $32 million, the company projects modest annual growth. However, the fundamental challenge remains: generating sufficient revenue and margin improvement to significantly reduce operating losses and eventually achieve positive cash flow before their capital resources are exhausted.
- Reports second quarter 2025 total revenue of
$7.3 million , representing10% growth compared to the second quarter of 2024.- Second quarter 2025 recurring revenue increased
15% compared to the second quarter of 2024.
- Second quarter 2025 recurring revenue increased
- Reports second quarter gross margin of
4% , representing a seven-percentage point improvement compared to the second quarter of 2024.
- Enters into five-year,
$45 million term loan facility with$20 million funded at close.
- Reaffirms full-year 2025 total revenue guidance of at least
$32.0 million .
LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025.
“Our second quarter results reflect broad-based, consistent execution across the business,” said Robert Spignesi, President and CEO. “Total revenue increased
“In addition, this morning we announced a new five-year,
Second Quarter Financial Results
Total revenue for the second quarter of 2025 increased
Total cost of revenue was
Total operating expenses decreased by
Net loss for the second quarter of 2025 was
Cash, cash equivalents, short-term investments, and restricted cash were approximately
2025 Outlook
The Company is reaffirming its full year 2025 total revenue guidance of at least
Loan Facility
In a separate release issued today, the Company announced that it has entered into a five-year,
For additional details regarding this facility, please refer to the related press release at https://investors.rapidmicrobio.com/news-and-events/news-releases.
Webcast Details
The Company will host a conference call before the market opens today, August 12, 2025, at 8:30 a.m. ET to discuss its second quarter 2025 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations and webcasts.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2025 total revenue and number of Growth Direct placements; the Company's goal of achieving cash flow breakeven; the Company's newly-announced debt facility; the Company’s ability to reduce product costs, and improve manufacturing efficiency and service productivity; and the Company's ability to advance its priorities of accelerating Growth Direct system placements, improving gross margins and innovating new products.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder, the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 4,802 | $ | 4,537 | $ | 8,903 | $ | 8,250 | ||||||||
| Service revenue | 2,460 | 2,081 | 5,564 | 3,979 | ||||||||||||
| Total revenue | 7,262 | 6,618 | 14,467 | 12,229 | ||||||||||||
| Costs and operating expenses: | ||||||||||||||||
| Cost of product revenue | 5,315 | 4,917 | 10,344 | 10,090 | ||||||||||||
| Cost of service revenue | 1,672 | 1,890 | 3,444 | 3,851 | ||||||||||||
| Research and development | 3,230 | 3,744 | 6,854 | 7,586 | ||||||||||||
| Sales and marketing | 3,114 | 3,627 | 5,865 | 6,908 | ||||||||||||
| General and administrative | 6,079 | 5,818 | 11,769 | 11,445 | ||||||||||||
| Total costs and operating expenses | 19,410 | 19,996 | 38,276 | 39,880 | ||||||||||||
| Loss from operations | (12,148 | ) | (13,378 | ) | (23,809 | ) | (27,651 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income, net | 351 | 838 | 817 | 1,821 | ||||||||||||
| Other expense, net | (50 | ) | (23 | ) | (111 | ) | (52 | ) | ||||||||
| Total other income, net | 301 | 815 | 706 | 1,769 | ||||||||||||
| Loss before income taxes | (11,847 | ) | (12,563 | ) | (23,103 | ) | (25,882 | ) | ||||||||
| Income tax expense | 11 | 15 | 18 | 18 | ||||||||||||
| Net loss | $ | (11,858 | ) | $ | (12,578 | ) | (23,121 | ) | (25,900 | ) | ||||||
| Net loss per share — basic and diluted | $ | (0.27 | ) | $ | (0.29 | ) | $ | (0.52 | ) | $ | (0.60 | ) | ||||
| Weighted average common shares outstanding — basic and diluted | 44,648,602 | 43,616,501 | 44,321,566 | 43,431,170 | ||||||||||||
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Balance Sheets (in thousands) | ||||||
| June 30, 2025 | December 31, 2024 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 18,333 | $ | 16,911 | ||
| Short-term investments | 12,922 | 33,821 | ||||
| Accounts receivable | 6,048 | 7,519 | ||||
| Inventory | 20,560 | 20,200 | ||||
| Prepaid expenses and other current assets | 2,283 | 2,466 | ||||
| Total current assets | 60,146 | 80,917 | ||||
| Property and equipment, net | 10,205 | 11,193 | ||||
| Right-of-use assets, net | 4,640 | 5,163 | ||||
| Other long-term assets | 311 | 531 | ||||
| Restricted cash | 284 | 365 | ||||
| Total assets | $ | 75,586 | $ | 98,169 | ||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 3,334 | $ | 2,535 | ||
| Accrued expenses and other current liabilities | 5,678 | 7,217 | ||||
| Deferred revenue | 6,136 | 6,599 | ||||
| Lease liabilities, short-term | 1,255 | 1,214 | ||||
| Total current liabilities | 16,403 | 17,565 | ||||
| Lease liabilities, long-term | 4,324 | 4,954 | ||||
| Other long-term liabilities | 314 | 298 | ||||
| Total liabilities | 21,041 | 22,817 | ||||
| Total stockholders’ equity | 54,545 | 75,352 | ||||
| Total liabilities and stockholders’ equity | $ | 75,586 | $ | 98,169 | ||
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Cash, Cash Equivalents and Investments (in thousands) | ||||||
| June 30, 2025 | December 31, 2024 | |||||
| Cash and cash equivalents | $ | 18,333 | $ | 16,911 | ||
| Short-term investments | 12,922 | 33,821 | ||||
| Cash, cash equivalents and investments | $ | 31,255 | $ | 50,732 | ||
Investor Contact Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact media@rapidmicrobio.com
FAQ
What were Rapid Micro Biosystems (RPID) Q2 2025 earnings results?
How much was RPID's new term loan facility and what are the terms?
What is RPID's revenue guidance for 2025?
How many Growth Direct systems did RPID place in Q2 2025?
What was RPID's recurring revenue growth in Q2 2025?
